SEARCH

SEARCH BY CITATION

References

  • 1
    Van Den Berg MM, Benninga MA, Di Lorenzo C. Epidemiology of childhood constipation: a systematic review. Am J Gastroenterol 2006; 101: 24019.
    Direct Link:
  • 2
    Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004; 99: 7509.
    Direct Link:
  • 3
    Dennison C, Prasad M, Lloyd A, Bhattacharyya SK, Dhawan R, Coyne K. The health-related quality of life and economic burden of constipation. Pharmacoeconomics 2005; 23: 46176.
  • 4
    Stewart WF, Liberman JN, Sandler RS et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol 1999; 94: 353040.
    Direct Link:
  • 5
    Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007; 25: 599608.
  • 6
    Glia A, Lindberg G. Quality of life in patients with different types of functional constipation. Scand J Gastroenterol 1997; 32: 10839.
  • 7
    Damon H, Dumas PFM. Impact of anal incontinence and chronic constipation on quality of life. Gastroenterol Clin Biol 2004; 28: 1620.
  • 8
    Irvine EJ, Ferrazzi S, Pare P, Thompson WG, Rance L. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol 2002; 97: 198693.
    Direct Link:
  • 9
    Wald A, Scarpignato C, Kamm MA et al. The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther 2007; 26: 22736.
  • 10
    Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol 2005; 40: 54051.
  • 11
    Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008; 358: 234454.
  • 12
    Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation; a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009; 29: 31528.
  • 13
    Tack J, Van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor®) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009; 58: 35765.
  • 14
    Camilleri M, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Submitted. 2009.
  • 15
    Lydick E, Epstein R. Interpretation of quality of life changes. Qual Life Res 1993; 2: 2216.
  • 16
    Frank LKL, Farup C, Taylor L, Miner P Jr. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999; 34: 8707.
  • 17
    Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36®): I. conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 18
    Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 1995; 273: 5965.
  • 19
    Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol 2005; 40: 54051.
  • 20
    Cronbach L. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297334.
  • 21
    Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 40715.
  • 22
    Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. and the Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77: 37183.
  • 23
    Sloan JA, Symonds T, Vargas-Chanes D, Fridley B. Practical guidelines for assessing the clinical significance of health related quality of life changes within clinical trials. Drug Inf J 2003; 37: 2331.
  • 24
    Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999; 37: 46978.
  • 25
    Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Hillsdale, NJ: Erlbaum, 1988.
  • 26
    Patrick DL, Burke LB, Powers JH et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007; 10: S12537.